Acadian Asset Management LLC Grows Position in Sensus Healthcare, Inc. $SRTS

Acadian Asset Management LLC grew its stake in Sensus Healthcare, Inc. (NASDAQ:SRTS) by 35.3% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 470,713 shares of the company’s stock after purchasing an additional 122,746 shares during the period. Acadian Asset Management LLC owned about 2.85% of Sensus Healthcare worth $2,225,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Sensus Healthcare during the 1st quarter worth approximately $71,000. Millennium Management LLC raised its stake in shares of Sensus Healthcare by 256.6% during the 4th quarter. Millennium Management LLC now owns 85,329 shares of the company’s stock worth $590,000 after buying an additional 61,403 shares during the period. IFP Advisors Inc raised its stake in shares of Sensus Healthcare by 37.2% during the 1st quarter. IFP Advisors Inc now owns 18,800 shares of the company’s stock worth $89,000 after buying an additional 5,100 shares during the period. Pacific Ridge Capital Partners LLC acquired a new position in shares of Sensus Healthcare during the 1st quarter worth approximately $542,000. Finally, Bank of New York Mellon Corp raised its stake in shares of Sensus Healthcare by 3.9% during the 1st quarter. Bank of New York Mellon Corp now owns 141,971 shares of the company’s stock worth $672,000 after buying an additional 5,289 shares during the period. 25.30% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on SRTS shares. Maxim Group reduced their target price on Sensus Healthcare from $14.00 to $10.00 and set a “buy” rating for the company in a research note on Monday, May 19th. Wall Street Zen cut Sensus Healthcare from a “hold” rating to a “sell” rating in a research report on Sunday, June 22nd. HC Wainwright dropped their price target on Sensus Healthcare from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Tuesday, August 12th. Finally, Lake Street Capital dropped their price target on Sensus Healthcare from $13.00 to $6.00 and set a “buy” rating for the company in a research report on Friday, August 8th. Three research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $8.00.

Sensus Healthcare Trading Down 0.9%

Shares of NASDAQ SRTS opened at $3.15 on Tuesday. Sensus Healthcare, Inc. has a twelve month low of $3.03 and a twelve month high of $9.33. The stock has a fifty day simple moving average of $4.03 and a 200-day simple moving average of $4.45. The stock has a market capitalization of $51.79 million, a PE ratio of -52.50 and a beta of 1.41.

Sensus Healthcare (NASDAQ:SRTS) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.07). Sensus Healthcare had a negative net margin of 2.26% and a negative return on equity of 1.58%. The firm had revenue of $7.32 million during the quarter, compared to analyst estimates of $9.30 million. On average, equities analysts predict that Sensus Healthcare, Inc. will post 0.32 earnings per share for the current year.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.